Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 5/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 9/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15115808 | 0.91 | LIMK1 (0.49) | LIMK1CSNK2A2CSNK2BCSNK2A1MKNK1 | |
| SCHEMBL15933742 | 0.89 | LIMK1 (0.77) | LIMK1CSNK2A2CSNK2BCSNK2A1MKNK1 | |
| SCHEMBL16751134 | 0.89 | LIMK1 (0.77) | LIMK1CSNK2A2CSNK2BCSNK2A1MKNK1 | |
| SCHEMBL16384793 | 0.89 | LIMK1 (0.77) | LIMK1CSNK2A2CSNK2BCSNK2A1MKNK1 | |
| SCHEMBL5629554 | 0.89 | LIMK1 (0.77) | LIMK1CSNK2A2CSNK2BCSNK2A1MKNK1 | |
| SCHEMBL18135597 | 0.87 | LIMK1 (0.61) | LIMK1CSNK2A2CSNK2BCSNK2A1MKNK1 | |
| SCHEMBL18135594 | 0.87 | LIMK1 (0.64) | LIMK1CSNK2A2CSNK2BCSNK2A1MKNK1 | |
| SCHEMBL18135596 | 0.87 | LIMK1 (0.64) | LIMK1CSNK2A2CSNK2BCSNK2A1MKNK1 | |
| SCHEMBL16384794 | 0.86 | LIMK1 (0.59) | LIMK1CSNK2A2CSNK2BCSNK2A1MKNK1 | |
| SCHEMBL16370982 | 0.86 | LIMK1 (0.59) | LIMK1CSNK2A2CSNK2BCSNK2A1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162877-A1 | PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162877-A1 | PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS | MKNK1, MKNK2, MAP4K5 | LIMK1 287/4885CSNK2A2 228/4885CSNK2B 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.